Edition:
United States

CTi Biopharma Corp (CTIC.O)

CTIC.O on Consolidated Issue listed on NASDAQ Capital Market

3.31USD
16 Oct 2017
Change (% chg)

$-0.00 (-0.15%)
Prev Close
$3.31
Open
$3.29
Day's High
$3.38
Day's Low
$3.29
Volume
216,959
Avg. Vol
150,556
52-wk High
$6.48
52-wk Low
$2.70

Latest Key Developments (Source: Significant Developments)

CTI Biopharma appoints Laurent Fischer as new board chairman
Tuesday, 26 Sep 2017 01:30am EDT 

Sept 26 (Reuters) - CTI Biopharma Corp :CTI Biopharma appoints Laurent Fischer as new chairman of the board and announces management promotions.Announces promotion of David Kirske to chief financial officer and Bruce Seeley to chief operating officer of company.  Full Article

CTI Biopharma announces european medicines agency validation of Pacritinib
Thursday, 13 Jul 2017 04:05pm EDT 

July 13 (Reuters) - Cti Biopharma Corp :CTI Biopharma announces european medicines agency validation of pacritinib marketing authorization application for patients with myelofibrosis who have thrombocytopenia.CTI Biopharma Corp - announced that european medicines agency (ema) has validated marketing authorization application (maa) for pacritinib.Says if authorized, pacritinib would be granted a marketing license valid in all 28 eu member states.  Full Article

Stonepine Capital Management LLC reports 7.6 pct passive stake in CTI Biopharma Corp as of June 6, 2017
Thursday, 22 Jun 2017 01:44pm EDT 

June 22 (Reuters) - Stonepine Capital Management LLC :Stonepine Capital Management LLC reports 7.6 percent passive stake in cti biopharma corp as of june 6, 2017 - SEC filing.  Full Article

Orbimed Advisors Llc reports 11.6 percent passive stake in CTI Biopharma Corp
Thursday, 15 Jun 2017 05:13pm EDT 

June 15 (Reuters) - Orbimed Advisors Llc: :Orbimed Advisors Llc reports 11.6 percent passive stake in CTI Biopharma Corp as of June 9 .  Full Article

CTI Biopharma announces proposed public offering of convertible preferred stock
Monday, 5 Jun 2017 04:02pm EDT 

June 5 (Reuters) - Cti Biopharma Corp :CTI Biopharma announces proposed public offering of convertible preferred stock.‍Each share of series N-3 preferred stock will have a stated value of $1,000 per share​.CTI plans to use net proceeds from this offering in part to conduct pac203 clinical trial, submit new MAA for pacritinib to EMA.  Full Article

CTi Biopharma reports Q1 revenue $800,000
Wednesday, 3 May 2017 04:01pm EDT 

May 3 (Reuters) - CTi Biopharma Corp :CTi Biopharma reports first quarter 2017 financial results.Q1 loss per share $0.71.Q1 revenue $800,000 versus $36.5 million.CTi Biopharma Corp - As of March 31, 2017, cash and cash equivalents totaled $33.3 million, compared to $44.0 million as of December 31, 2016.  Full Article

CTI Biopharma announces license and agreement expansion with Servier to commercialize Pixuvri
Tuesday, 25 Apr 2017 01:30am EDT 

April 25 (Reuters) - Cti Biopharma Corp ::Servier and CTI biopharma expand license and collaboration agreement to develop and commercialize Pixuvri.Servier will commercialize Pixuvri in all markets except the US.Will retain rights to commercialize Pixuvri in the US.Servier will pay Co 12 million euros ($13.0 million) with potential for Co to receive eur 76 million in additional sales and regulatory milestone payments as well as royalties on net product sales.  Full Article

Servier,CTI Biopharma expand Pixuvri license and collaboration agreement
Tuesday, 25 Apr 2017 01:30am EDT 

April 25 (Reuters) - Cti Biopharma Corp :Servier and CTI Biopharma expand license and collaboration agreement to develop and commercialize Pixuvri.Says Servier will commercialize Pixuvri in all markets except US.Says CTI Biopharma will retain rights to commercialize Pixuvri in US.CTI Biopharma - Servier to pay CO EUR 12 million with potential for CO to receive EUR 76 million in additional sales and regulatory milestone payments.CTI Biopharma - as specific post-authorization requirement, Pixuvri is currently being investigated in a phase iii clinical trial, pix306.CTI Biopharma - Pixuvri granted conditional marketing authorization from European Commission.  Full Article

CTI Biopharma Q4 loss per share $0.23
Thursday, 2 Mar 2017 04:01pm EST 

Cti Biopharma Corp : Cti biopharma reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.23 .Total revenues for q4 $9.1 million compared to $11.3 million.  Full Article

CTi Biopharma announces phase 3 data from the PERSIST-2 trial of Pacritinib to be presented in late-breaking session at ASH annual meeting
Monday, 21 Nov 2016 04:01pm EST 

CTi Biopharma Corp :CTi Biopharma announces phase 3 data from the PERSIST-2 trial of Pacritinib to be presented in late-breaking session at ASH annual meeting.  Full Article

BrainStorm enrolls first patients in advanced ALS stem cell trial

TEL AVIV BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California.